Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refnot in Advanced Solid Tumors
NCT05898451Phase 2Completed
- Sponsor
- Refnot-Pharm
- Start
- Jun 2009
- Primary completion
- Nov 2011
- Modality
- Cytokines & Interferons, Peptides, Fc-Fusion Proteins
01
Overview
Phase 2, open-label trial of Refnot in solid tumor (2 arms), sponsored by Refnot-Pharm. Primary endpoints: Change in the level of CD3+ cells at 4 weeks, Change in the level of CD4+ cells at 4 weeks and 3 more. Started Jun 2009; status: completed.
02
Drugs
Refnot
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05898451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05898451.